◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ACHV

Achieve Life Sciences Inc (ACHV) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Achieve Life Sciences Inc (ACHV) operates in the BIOTECHNOLOGY industry and is headquartered in Bothell, United States with about 28 employees. Its market capitalization is roughly $776 million. In the fiscal year ended 2025-12-31, ACHV reported $0M in revenue and ($55M) in net income.

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

Interactive charts & full statements →

ACHV Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$5M	$18M	$27M	$30M	$20M	$5M	$14M	$26M	$20M	$20M	$22M
Gross Profit	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$5M	$18M	$27M	$30M	$20M	$5M	$14M	$26M	$20M	$20M	$22M
Gross Margin %	—	—	—	—	—	—	—	—	—	—	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($58M)	($55M)	($39M)	($27M)	($41M)	($33M)	($15M)	($17M)	($13M)	($7M)	($21M)	($19M)	($29M)	($35M)	($26M)	($22M)	($15M)	($2M)	($6M)	($15M)	($26M)
Operating Margin %	—	—	—	—	—	—	—	—	—	—	-418.6%	-103.3%	-108.7%	-118.2%	-129.3%	-405.5%	-108.3%	-9.7%	-31.1%	-75.7%	-117.4%
Net Income	($114M)	($55M)	($40M)	($30M)	($42M)	($33M)	($15M)	($16M)	($13M)	($11M)	($20M)	($17M)	($26M)	($32M)	($21M)	($15M)	($13M)	$5M	($4M)	($13M)	($24M)
Net Margin %	—	—	—	—	—	—	—	—	—	—	-397.7%	-92.5%	-96.8%	-106.6%	-105.0%	-267.0%	-92.4%	21.4%	-20.9%	-64.9%	-105.2%
EBITDA	($113M)	($54M)	($37M)	($27M)	($41M)	($33M)	($14M)	($16M)	($13M)	($13M)	($20M)	($19M)	($26M)	($32M)	($21M)	($22M)	($16M)	$1M	($11M)	($12M)	($23M)
Earnings Per Share (EPS)	$-1.55	$-1.25	$-1.24	$-1.50	$-3.95	$-4.05	$-5.39	$-39.15	$-72.29	$-441.47	$-1,474.98	$-1,413.63	$-3,189.89	$-4,772.10	$-3,432.80	$-3,318.18	$-3,938.65	$2,124.95	$-1,677.57	$-13,971.30	$-25,323.97
Shares Outstanding (M)	94M	44M	32M	20M	11M	8M	3M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACHV Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Margin %	—	—	—	—	—	—	50.0%	—
Operating Income (EBIT)	($18M)	($10M)	($15M)	($15M)	($13M)	($13M)	($12M)	($12M)
Operating Margin %	—	—	—	—	—	—	-5346.5%	—
Net Income	($75M)	($10M)	($15M)	($14M)	($13M)	($13M)	($12M)	($13M)
Net Margin %	—	—	—	—	—	—	-5421.1%	—
EBITDA	($74M)	($10M)	($14M)	($14M)	($12M)	($13M)	($12M)	($12M)
Earnings Per Share (EPS)	$-0.80	$-0.19	$-0.28	$-0.28	$-0.37	$-0.37	$-0.36	$-0.36
Shares Outstanding (M)	94M	53M	53M	51M	35M	35M	35M	34M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACHV Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($47M)	($49M)	($30M)	($24M)	($38M)	($29M)	($13M)	($15M)	($11M)	($9M)	($30M)	($9M)	($17M)	($36M)	($43M)	($20M)	($27M)	$35M	($12M)	($23M)	($20M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$1M
Free Cash Flow (FCF)	($47M)	($49M)	($30M)	($24M)	($38M)	($29M)	($13M)	($15M)	($11M)	($9M)	($30M)	($9M)	($17M)	($36M)	($44M)	($20M)	($27M)	$35M	($12M)	($25M)	($20M)
FCF Margin %	—	—	—	—	—	—	—	—	—	—	-587.3%	-52.2%	-64.1%	-121.1%	-217.9%	-370.1%	-197.6%	136.5%	-61.2%	-122.8%	-91.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACHV Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($11M)	($7M)	($18M)	($11M)	($9M)	($11M)	($9M)	($10M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($11M)	($7M)	($18M)	($11M)	($9M)	($11M)	($9M)	($10M)
FCF Margin %	—	—	—	—	—	—	-4030.3%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACHV Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$190M	$42M	$39M	$19M	$30M	$48M	$40M	$21M	$19M	$10M	$27M	$58M	$56M	$56M	$82M	$68M	$90M	$69M	$15M	$45M	$68M
Cash & Cash Equivalents	$48M	$21M	$13M	$16M	$25M	$43M	$36M	$17M	$10M	$5M	$15M	$34M	$28M	$15M	$18M	$29M	$24M	$62M	$8M	$7M	$36M
Total Liabilities	$205M	$20M	$18M	$21M	$22M	$19M	$3M	$3M	$3M	$2M	$9M	$21M	$22M	$18M	$16M	$37M	$46M	$46M	$4M	$13M	$25M
Total Debt (Short + Long-Term)	$15M	$15M	$10M	$17M	$32M	$15M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$1M	$1M	$1M	$1M	$1M	$1M	$0M	$0M
Total Shareholders' Equity	($15M)	$22M	$21M	($1M)	$8M	$28M	$37M	$18M	$16M	$8M	$19M	$37M	$34M	$37M	$66M	$31M	$44M	$23M	$11M	$32M	$43M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACHV viewer.

Other Companies in BIOTECHNOLOGY

CTMX · CytomX Therapeutics Inc — $808 million
CLYM · Climb Bio Inc — $807 million
FDMT · 4D Molecular Therapeutics Inc — $779 million
DBVT · DBV Technologies — $776 million
CBIO · Crescent Biopharma, Inc. — $776 million
DSGN · Design Therapeutics Inc — $766 million
NGNE · Neurogene Inc — $758 million
MNPR · Monopar Therapeutics Inc — $754 million

← ACHR All “A” companies ACHX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.